Skip to main content

Advertisement

Log in

Diabetes mellitus and risk of prostate cancer: an updated meta-analysis based on 12 case–control and 25 cohort studies

Acta Diabetologica Aims and scope Submit manuscript

Abstract

The association between diabetes and risk of prostate cancer has been investigated widely. However, study results remain inconsistent and contradictory. Using a meta-analytic approach, the present study explore the relationship incorporating more recent studies and provide more powerful evidence without the limitations of any individual study. Relevant studies were identified by searching Pubmed and the Cochrane Central Register of Controlled Trials through May 18, 2012. The strength of the relationship between diabetes mellitus and risk of prostate cancer was assessed using relative risk (RR). Either a fixed effects or random effects model was used to calculate the pooled RRs. Stratification analyses and sensitivity analyses were conducted, and publication bias was assessed by Egger’s test and Begg’s test. Twelve case–control studies involving 9,767 cases and 19,790 controls, and 25 cohort studies involving 118,825 cases were included. The person-years of follow-up ranged from 29,963 to 6,264,890 among included cohort studies. Diabetes was not significantly associated with incidence of prostate cancer in our analysis of case–control studies only (RR = 0.846, 95 % CI [0.710, 1.009]) or that of cohort studies only (RR = 0.925, 95 % CI [0.811, 1.054]). However, through subgroup analyses, statistically significant associations between diabetes and prostate cancer were found when considering population-based studies only (RR = 0.719, 95 % CI [0.637, 0.812]), cohort studies conducted in the United States (RR = 0.789, 95 % CI [0.727, 0.857]), and studies with follow-up of more than 5 years. Compared to risk of prostate cancer among people without diabetes, diabetic patients using insulin treatment experienced reduced incidence of prostate cancer in both case–control and cohort studies. The results suggest that diabetes mellitus is associated with decreased incidence of prostate cancer, specifically in the population of the United States. In addition, the time since onset of diabetes was positively associated with decreasing incidence of prostate cancer. The present conclusions should be considered carefully, however, and confirmed with further studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. Deng L, Gui Z, Zhao L, Wang J, Shen L (2012) Diabetes mellitus and the incidence of colorectal cancer: an updated systematic review and meta-analysis. Dig Dis Sci 57(6):1576–1585

    Article  PubMed  CAS  Google Scholar 

  2. Wang P, Kang D, Cao W, Wang Y, Liu Z (2012) Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis. Diabetes Metab Res Rev 28(2):109–122

    Article  PubMed  Google Scholar 

  3. Ben Q, Xu M, Ning X et al (2011) Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies. Eur J Cancer 47(13):1928–1937

    Article  PubMed  Google Scholar 

  4. Onishi S, Takemoto M, Ishikawa T et al. (2012) Japanese diabetic patients with Werner syndrome exhibit high incidence of cancer. Acta Diabetol. doi:10.1007/s00592-012-0424-z

  5. Nicolucci A (2010) Epidemiological aspects of neoplasms in diabetes. Acta Diabetol 47(2):87–95

    Article  PubMed  Google Scholar 

  6. Bonovas S, Filioussi K, Tsantes A (2004) Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia 47(6):1071–1078

    Article  PubMed  CAS  Google Scholar 

  7. Kasper JS, Giovannucci E (2006) A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15(11):2056–2062

    Article  PubMed  Google Scholar 

  8. Wallström P, Bjartell A, Gullberg B, Olsson H, Wirfält E (2009) A prospective Swedish study on body size, body composition, diabetes, and prostate cancer risk. Br J Cancer 100(11):1799–1805

    Article  PubMed  Google Scholar 

  9. Martin RM, Vatten L, Gunnell D, Romundstad P, Nilsen TI (2009) Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort. Norway. Cancer Causes Control 20(7):1181–1192

    Article  Google Scholar 

  10. Lee MY, Lin KD, Hsiao PJ, Shin SJ (2012) The association of diabetes mellitus with liver, colon, lung, and prostate cancer is independent of hypertension, hyperlipidemia, and gout in Taiwanese patients. Metabolism 61(2):242–249

    Article  PubMed  CAS  Google Scholar 

  11. Tseng CH (2011) Diabetes and risk of prostate cancer: a study using the National Health Insurance. Diabetes Care 34(3):616–621

    Article  PubMed  Google Scholar 

  12. Li Q, Kuriyama S, Kakizaki M et al (2010) History of diabetes mellitus and the risk of prostate cancer: the Ohsaki Cohort Study. Cancer Causes Control 21(7):1025–1032

    Article  PubMed  Google Scholar 

  13. Chodick G, Heymann AD, Rosenmann L et al (2010) Diabetes and risk of incident cancer: a large population-based cohort study in Israel. Cancer Causes Control 21(6):879–887

    Article  PubMed  Google Scholar 

  14. Moses KA, Utuama OA, Goodman M, Issa MM (2012) The association of diabetes and positive prostate biopsy in a US veteran population. Prostate Cancer Prostatic Dis 15(1):70–74

    Article  PubMed  CAS  Google Scholar 

  15. Ganesh B, Saoba SL, Sarade MN, Pinjari SV (2011) Risk factors for prostate cancer: an hospital-based case-control study from Mumbai, India. Indian J Urol 27(3):345–350

    Article  PubMed  CAS  Google Scholar 

  16. Pelucchi C, Serraino D, Negri E, Montella M, Dellanoce C, Talamini R, La Vecchia C (2011) The metabolic syndrome and risk of prostate cancer in Italy. Ann Epidemiol 21(11):835–841

    Article  PubMed  Google Scholar 

  17. Wu C, Moreira DM, Gerber L, Rittmaster RS, Andriole GL, Freedland SJ (2011) Diabetes and prostate cancer risk in the REDUCE trial. Prostate Cancer Prostatic Dis 14(4):326–331

    Article  PubMed  CAS  Google Scholar 

  18. Turner EL, Lane JA, Donovan JL et al (2011) Association of diabetes mellitus with prostate cancer: nested case-control study (Prostate testing for cancer and treatment study). Int J Cancer 128(2):440–446

    Article  PubMed  CAS  Google Scholar 

  19. Baradaran N, Ahmadi H, Salem S et al (2009) The protective effect of diabetes mellitus against prostate cancer: role of sex hormones. Prostate 69(16):1744–1750

    Article  PubMed  CAS  Google Scholar 

  20. Pierce BL, Plymate S, Ostrander EA, Stanford JL (2008) Diabetes mellitus and prostate cancer risk. Prostate 68(10):1126–1132

    Article  PubMed  Google Scholar 

  21. Johnson JA, Bowker SL, Richardson K, Marra CA (2011) Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias. Diabetologia 54(9):2263–2271

    Article  PubMed  CAS  Google Scholar 

  22. Wallner LP, Morgenstern H, McGree ME et al (2011) The effects of metabolic conditions on prostate cancer incidence over 15 years of follow-up: results from the Olmsted County Study. BJU Int 107(6):929–935

    Article  PubMed  Google Scholar 

  23. Grundmark B, Garmo H, Loda M, Busch C, Holmberg L, Zethelius B (2010) The metabolic syndrome and the risk of prostate cancer under competing risks of death from other causes. Cancer Epidemiol Biomarkers Prev 19(8):2088–2096

    Article  PubMed  Google Scholar 

  24. Atchison EA, Gridley G, Carreon JD, Leitzmann MF, McGlynn KA (2011) Risk of cancer in a large cohort of US veterans with diabetes. Int J Cancer 128(3):635–643

    Article  PubMed  CAS  Google Scholar 

  25. Waters KM, Henderson BE, Stram DO, Wan P, Kolonel LN, Haiman CA (2009) Association of diabetes with prostate cancer risk in the multiethnic cohort. Am J Epidemiol 169(8):937–945

    Article  PubMed  Google Scholar 

  26. Kasper JS, Liu Y, Giovannucci E (2009) Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study. Int J Cancer 124(6):1398–1403

    Article  PubMed  CAS  Google Scholar 

  27. Leitzmann MF, Ahn J, Albanes D et al (2008) Diabetes mellitus and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Causes Control 19(10):1267–1276

    Article  PubMed  Google Scholar 

  28. Darbinian JA, Ferrara AM, Van Den Eeden SK, Quesenberry CP Jr, Fireman B, Habel LA (2008) Glycemic status and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 17(3):628–635

    Article  PubMed  CAS  Google Scholar 

  29. Calton BA, Chang SC, Wright ME et al (2007) History of diabetes mellitus and subsequent prostate cancer risk in the NIH-AARP Diet and Health Study. Cancer Causes Control 18(5):493–503

    Article  PubMed  Google Scholar 

  30. Gong Z, Neuhouser ML, Goodman PJ et al (2006) Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 15(10):1977–1983

    Article  PubMed  Google Scholar 

  31. Velicer CM, Dublin S, White E (2007) Diabetes and the risk of prostate cancer: the role of diabetes treatment and complications. Prostate Cancer Prostatic Dis 10(1):46–51

    Article  PubMed  CAS  Google Scholar 

  32. Tande AJ, Platz EA, Folsom AR (2006) The metabolic syndrome is associated with reduced risk of prostate cancer. Am J Epidemiol 164(11):1094–1102

    Article  PubMed  Google Scholar 

  33. Johnson JA, Bowker SL (2011) Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia 54(1):25–31

    Article  PubMed  CAS  Google Scholar 

  34. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330:1304–1305

    Article  PubMed  Google Scholar 

  35. Hitron A, Adams V, Talbert J, Steinke D (2012) The influence of antidiabetic medications on the development and progression of prostate cancer. Cancer Epidemiol 36(4):e243–e250

    Article  PubMed  CAS  Google Scholar 

  36. Chang CH, Toh S, Lin JW et al (2011) Cancer risk associated with insulin glargine among adult type 2 diabetes patients–a nationwide cohort study. PLoS ONE 6(6):e21368

    Article  PubMed  CAS  Google Scholar 

  37. Ben Sahra I, Laurent K, Giuliano S et al (2010) Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res 70(6):2465–2475

    Article  PubMed  CAS  Google Scholar 

  38. Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H (2009) Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes Metab Res Rev. 25(1):41–49

    Article  PubMed  CAS  Google Scholar 

  39. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535

    Article  PubMed  Google Scholar 

  40. Little J, Bradley L, Bray MS et al (2002) Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. Am J Epidemiol 156:300–310

    Article  PubMed  Google Scholar 

  41. Crowther M, Lim W, Crowther MA (2010) Systematic review and meta-analysis methodology. Blood 116(17):3140–3146

    Article  PubMed  CAS  Google Scholar 

  42. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188

    Article  PubMed  CAS  Google Scholar 

  43. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101

    Article  PubMed  CAS  Google Scholar 

  44. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634

    Article  PubMed  CAS  Google Scholar 

  45. Tavani A, Gallus S, Bertuzzi M et al (2005) Diabetes mellitus and the risk of prostate cancer in Italy. Eur Urol 47(3):313–317

    Article  PubMed  CAS  Google Scholar 

  46. González-Pérez A, García Rodríguez LA (2005) Prostate cancer risk among men with diabetes mellitus (Spain). Cancer Causes Control 16(9):1055–1058

    Article  PubMed  Google Scholar 

  47. Coker AL, Sanderson M, Zheng W, Fadden MK (2004) Diabetes mellitus and prostate cancer risk among older men: population-based case-control study. Br J Cancer 90(11):2171–2175

    PubMed  CAS  Google Scholar 

  48. Zhu K, Lee IM, Sesso HD, Buring JE, Levine RS, Gaziano JM (2004) History of diabetes mellitus and risk of prostate cancer in physicians. Am J Epidemiol 159(10):978–982

    Article  PubMed  CAS  Google Scholar 

  49. Tavani A, Gallus S, Bosetti C et al (2002) Diabetes and the risk of prostate cancer. Eur J Cancer Prev 11(2):125–128

    Article  PubMed  CAS  Google Scholar 

  50. Rosenberg DJ, Neugut AI, Ahsan H, Shea S (2002) Diabetes mellitus and the risk of prostate cancer. Cancer Invest 20(2):157–165

    Article  PubMed  Google Scholar 

  51. Rodriguez C, Patel AV, Mondul AM, Jacobs EJ, Thun MJ, Calle EE (2005) Diabetes and risk of prostate cancer in a prospective cohort of US men. Am J Epidemiol 161(2):147–152

    Article  PubMed  Google Scholar 

  52. Weiderpass E, Ye W, Vainio H, Kaaks R, Adami HO (2002) Reduced risk of prostate cancer among patients with diabetes mellitus. Int J Cancer 102(3):258–261

    Article  PubMed  CAS  Google Scholar 

  53. Will JC, Vinicor F, Calle EE (1999) Is diabetes mellitus associated with prostate cancer incidence and survival? Epidemiology 10(3):313–318

    Article  PubMed  CAS  Google Scholar 

  54. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Willett WC (1998) Diabetes mellitus and risk of prostate cancer (United States). Cancer Causes Control 9(1):3–9

    Article  PubMed  CAS  Google Scholar 

  55. Wideroff L, Gridley G, Mellemkjaer L et al (1997) Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 89:1360–1365

    Article  PubMed  CAS  Google Scholar 

  56. Smith GD, Egger M, Shipley MJ, Marmot MG (1992) Post-challenge glucose concentration, impaired glucose tolerance, diabetes, and cancer mortality in men. Am J Epidemiol 136:1110–1114

    PubMed  CAS  Google Scholar 

  57. Coughlin SS, Neaton JD, Sengupta A (1996) Cigarette smoking as a predictor of death from prostate cancer in 348,874 men screened for the multiple risk factor intervention trial. Am J Epidemiol 143:1002–1006

    Article  PubMed  CAS  Google Scholar 

  58. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ (1996) Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 88(16):1118–1126

    Article  PubMed  CAS  Google Scholar 

  59. Corona G, Monami M, Rastrelli G et al (2011) Type 2 diabetes mellitus and testosterone: a meta-analysis study. Int J Androl 34(6 Pt 1):528–540

    Article  PubMed  CAS  Google Scholar 

  60. Gatenby VK, Kearney MT (2010) The role of IGF-1 resistance in obesity and type 2 diabetes-mellitus-related insulin resistance and vascular disease. Expert Opin Ther Targets 14(12):1333–1342

    Article  PubMed  CAS  Google Scholar 

  61. Cohen P, Peehl DM, Lamson G, Rosenfeld RG (1991) Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J Clin Endocrinol Metab 73:401–407

    Article  PubMed  CAS  Google Scholar 

  62. Rowlands MA, Gunnell D, Harris R, Vatten LJ, Holly JM, Martin RM (2009) Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis. Int J Cancer 124(10):2416–2429

    Article  PubMed  CAS  Google Scholar 

  63. Hsing AW, Chua S Jr, Gao YT et al (2001) Prostate cancer risk and serum levels of insulin and leptin: a population-based study. J Natl Cancer Inst 93:783–789

    Article  PubMed  CAS  Google Scholar 

  64. Lehrer S, Diamond EJ, Stagger S, Stone NN, Stock RG (2002) Increased serum insulin associated with increased risk of prostate cancer recurrence. Prostate 50:1–3

    Article  PubMed  Google Scholar 

  65. Perseghin G, Calori G, Lattuada G et al. (2012) Insulin resistance/hyperinsulinemia and cancer mortality: the Cremona study at the 15th year of follow-up. Acta Diabetol. doi:10.1007/s00592-011-0361-2

  66. Wells GA, Shea B, O’Connell D et al. (2012) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm Cited 19 June 2012

  67. Yang X, So WY, Ma RC et al. (2012) Synergistic effects of low LDL cholesterol with other factors for the risk of cancer in type 2 diabetes: the Hong Kong Diabetes Registry. Acta Diabetol. doi:10.1007/s00592-012-0409-y

Download references

Acknowledgments

We thank and Lijun Zhang (PhD, Chongqing Medical University, Chongqing, China) for finding the full text of relevant articles.

Conflict of interest

The authors declare that they have no competing interests.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Han Lei.

Additional information

Communicated by Massimo Federici.

The author F. Zhang and Y. Yang contributed equally to this study.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhang, F., Yang, Y., Skrip, L. et al. Diabetes mellitus and risk of prostate cancer: an updated meta-analysis based on 12 case–control and 25 cohort studies. Acta Diabetol 49 (Suppl 1), 235–246 (2012). https://doi.org/10.1007/s00592-012-0439-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00592-012-0439-5

Keywords

Navigation